Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial.
Chafic KaramDuncan BrownMin YangNicolae DoneJing Jing ZhuAlexandra GreatsingerAna BozasMontserrat Vera-LlonchJames SignorovitchPublished in: Muscle & nerve (2022)
Long-term (>3 years) inotersen treatment was associated with slowing and, in some domains, halting of deterioration in key HRQL outcome measures, particularly physical functioning and pain.